Abpro Holdings, Inc.
Abpro Holdings, Inc.
Your view on ABPO
Overview
What the company does, where it operates, and who runs it.
About Abpro Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jin Wook Suk
- Headquarters
- 100 Summit Drive, Burlington, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jin Wook Suk
- Headquarters
- 100 Summit Drive, Burlington, MA, US
Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology. The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration. The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Abpro Holdings, Inc., and the rating behind it. ABPO last traded at $0.25, 0.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Abpro Holdings, Inc.. Starting points for Abpro Holdings, Inc.: P/E 0.3, EPS $0.76, beta 0.15 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Abpro Holdings, Inc.. Abpro Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Abpro Holdings, Inc.. Trailing twelve-month EPS for Abpro Holdings, Inc. stands at $0.76. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Abpro Holdings, Inc.. Abpro Holdings, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Abpro Holdings, Inc. valued side by side against its closest peers. Abpro Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Abpro Holdings, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Abpro Holdings, Inc. executives and directors. Shares of Abpro Holdings, Inc. have traded between $0.09 and $8.49 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Abpro Holdings, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Abpro Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Abpro Holdings, Inc.. Coverage tracks Abpro Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.